Application of compound kushen injection in preparation of medicine for treating chronic hepatic fibrosis

Abstract

The invention provides an application of a compound kushen (radix sophorae flavescentis) injection in preparing a medicine for treating chronic hepatic fibrosis. The compound kushen injection can also be applied in repairing liver injury, and liver tissues are recovered to be normal by inhibiting the deposition of collagen in the liver; in addition, the compound kushen injection can also inhibit activation of hepatic stellate cells, and the medicine is prepared by inhibiting activation of the hepatic stellate cells to treat chronic hepatic fibrosis; the medicine for treating chronic hepatic fibrosis is prepared by down-regulating the expression of hepatic stellate cell activators; the medicine for treating chronic hepatic fibrosis is prepared by selectively inhibiting hepatic stellate cell activation; and the medicine for treating chronic hepatic fibrosis is prepared by intervening activation of a TGF-beta / Smad signal axis in hepatic stellate cells. Compared with the lack of approved drugs for treating hepatic fibrosis in clinic at present, the application of the compound kushen injection disclosed by the invention shows that the compound kushen injection can be used as a promising candidate drug for preventing or treating hepatic fibrosis and preventing the progression of hepatic fibrosis in clinical application.

Description

technical field [0001] The invention belongs to the technical field of new drug function development, and specifically relates to the application of a compound flavescens injection in the preparation of a drug for treating chronic liver fibrosis. Background technique [0002] Compound kushen injection (CKI), as a classic Chinese herbal compound preparation, has been approved by the National Medical Products Administration (NMPA) for the clinical treatment of pain caused by cancer. However, the specific mechanism of compound matrine injection in treating chronic liver fibrosis and alleviating the progression of liver fibrosis to hepatocellular carcinoma is still unclear. [0003] Hepatic fibrosis is the pathological result of liver caused by chronic or recurrent liver inflammation or liver injury, and can generally be defined as a continuous damage repair process that occurs inside the liver. The most important feature of liver fibrosis is the imbalance of excessive depositi...

AI Technical Summary

Problems solved by technology

Although there are many compounds or Chinese herbal medicines that have shown good therapeutic effects on liver fibrosis in vivo and in vitro cell experiments, none of the compounds or Chinese herbal medicines has been fully commercialized and approved for clinical liver fibrosis. First-line treatment modality for patients with fibrosis

Meanwhile, in preclinical and clinical studies, direct targeting of TGF-β signaling by neutralizing TGF-β in vivo or blocking TGF-β receptors may lead to multiple biological environment-dependent functions of TGF-β. Serious adverse reactions in vivo

Images